Clinical Study on the Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Nab-Paclitaxel in Neoadjuvant Therapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
Latest Information Update: 01 Apr 2026
At a glance
- Drugs Iparomlimab/tuvonralimab (Primary) ; Paclitaxel
- Indications Oesophageal cancer; Squamous cell cancer
- Focus Therapeutic Use
Most Recent Events
- 01 Apr 2026 New trial record